12,358 Shares of Intuitive Surgical, Inc. $ISRG Bought by Pensioenfonds Rail & OV

Pensioenfonds Rail & OV bought a new stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor bought 12,358 shares of the medical equipment provider’s stock, valued at approximately $5,025,000. Intuitive Surgical accounts for about 1.3% of Pensioenfonds Rail & OV’s investment portfolio, making the stock its 27th biggest holding.

Other hedge funds have also bought and sold shares of the company. Trillium Asset Management LLC boosted its stake in shares of Intuitive Surgical by 78.4% during the 3rd quarter. Trillium Asset Management LLC now owns 50,395 shares of the medical equipment provider’s stock worth $20,493,000 after acquiring an additional 22,145 shares during the period. Phoenix Financial Ltd. raised its stake in Intuitive Surgical by 30.3% in the 3rd quarter. Phoenix Financial Ltd. now owns 12,657 shares of the medical equipment provider’s stock valued at $4,861,000 after acquiring an additional 2,940 shares during the period. Migdal Insurance & Financial Holdings Ltd. raised its stake in Intuitive Surgical by 10.9% in the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 347 shares of the medical equipment provider’s stock valued at $141,000 after acquiring an additional 34 shares during the period. Dogwood Wealth Management LLC lifted its holdings in Intuitive Surgical by 178.3% during the 3rd quarter. Dogwood Wealth Management LLC now owns 64 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 41 shares during the last quarter. Finally, Cornerstone Advisory LLC lifted its holdings in Intuitive Surgical by 39.2% during the 3rd quarter. Cornerstone Advisory LLC now owns 809 shares of the medical equipment provider’s stock valued at $329,000 after purchasing an additional 228 shares during the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ISRG. BMO Capital Markets reaffirmed an “outperform” rating on shares of Intuitive Surgical in a research report on Monday, July 20th. JPMorgan Chase & Co. raised their target price on shares of Intuitive Surgical from $450.00 to $475.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 21st. BNP Paribas Exane raised shares of Intuitive Surgical to an “outperform” rating in a report on Tuesday, July 28th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Intuitive Surgical in a report on Thursday. Finally, Zacks Research upgraded Intuitive Surgical from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 22nd. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $493.54.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, EVP Gary Loeb sold 400 shares of the firm’s stock in a transaction on Tuesday, November 10th. The stock was sold at an average price of $458.15, for a total transaction of $183,260.00. Following the transaction, the executive vice president owned 6,236 shares in the company, valued at $2,857,023.40. This trade represents a 6.03% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Craig Barratt sold 1,150 shares of the firm’s stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $460.00, for a total value of $529,000.00. Following the transaction, the director owned 1,150 shares in the company, valued at approximately $529,000. This trade represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 39,456 shares of company stock valued at $17,769,124 over the last ninety days. 0.60% of the stock is owned by corporate insiders.

Intuitive Surgical Trading Up 0.8%

NASDAQ ISRG traded up $3.70 during trading on Friday, reaching $443.59. The company’s stock had a trading volume of 1,604,248 shares, compared to its average volume of 2,787,457. The firm has a 50 day moving average price of $417.59 and a 200 day moving average price of $429.98. Intuitive Surgical, Inc. has a 12 month low of $328.57 and a 12 month high of $603.88. The firm has a market capitalization of $153.77 billion, a price-to-earnings ratio of 53.64, a price-to-earnings-growth ratio of 3.03 and a beta of 1.45.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Tuesday, October 20th. The medical equipment provider reported $3.00 earnings per share for the quarter, beating analysts’ consensus estimates of $2.65 by $0.35. Intuitive Surgical had a net margin of 25.54% and a return on equity of 18.17%. The company had revenue of $3.05 billion during the quarter, compared to the consensus estimate of $2.91 billion. During the same period in the previous year, the business earned $2.40 earnings per share. The firm’s quarterly revenue was up 21.7% on a year-over-year basis. On average, equities analysts forecast that Intuitive Surgical, Inc. will post 9.37 EPS for the current fiscal year.

About Intuitive Surgical

Intuitive Surgical develops, manufactures and markets robotic-assisted systems for minimally invasive procedures. Its products include da Vinci surgical systems, which allow surgeons to control instruments and a high-definition vision system from a console, as well as the Ion endoluminal system, designed to assist with minimally invasive lung biopsies. The company also provides instruments, accessories, training and support services for its systems. Its technology is used in a range of surgical specialties, including urology, general surgery and gynecology.